Biorestorative Therapies Inc Stock Price, News & Analysis

BioRestorative Therapies (NASDAQ: BRTX) entered definitive agreements to sell 678,125 common shares at $1.60 per share in a registered direct offering, compared with a close of $1.50 on Oct 3, 2025. In a concurrent private placement, the company will issue unregistered warrants covering 508,594 shares (75% warrant coverage) with a $2.75 exercise price, exercisable six months after issuance through five years. Gross proceeds are $1.085 million before fees. Closing expected on or about Oct 8, 2025. Net proceeds will fund BRTX-100 clinical trials, ThermoStem preclinical R&D, biocosmeceuticals development, and general corporate purposes.

BioRestorative Therapies (NASDAQ:BRTX) reported its Q2 2025 financial results and business updates. The company achieved revenues of $303,000, marking a 240% increase from Q2 2024, primarily from BioCosmeceutical sales. The quarter ended with a net loss of $2.7 million ($0.30 per share), improved from a $4.0 million loss in Q2 2024.

Key developments include promising preliminary data from the BRTX-100 Phase 2 clinical trial for chronic lumbar disc disease, showing >50% improvement in both ODI and VAS metrics. The company maintains a strong financial position with $7.4 million in cash and investments with no debt. Additionally, BRTX announced a $2 million stock repurchase program through June 2026.

BioRestorative Therapies (NASDAQ:BRTX), a clinical stage regenerative medicine company specializing in stem cell-based therapies, has scheduled its second quarter 2025 financial results announcement for August 12, 2025, after market close.

The company will host a conference call at 4:30 p.m. ET to discuss the results and provide business updates. Investors can join via domestic (1-888-506-0062) or international (1-973-528-0011) lines using access code 436077. The call will be available for replay on the company's website.

BioRestorative Therapies (NASDAQ:BRTX), a clinical stage regenerative medicine company specializing in stem cell-based therapies, has announced that CEO Lance Alstodt will be interviewed on the Benzinga All-Access Show on June 18, 2025, at 10:50 a.m. Eastern time. During the interview, the company plans to discuss BRTX-100 clinical data, leadership changes, and strategic updates. The interview will be accessible via live webcast and will later be archived on the company's website in the Investors section.

BioRestorative Therapies (NASDAQ:BRTX), a clinical stage regenerative medicine company, has announced a $2 million share repurchase program effective through June 16, 2026. The company's Board of Directors authorized the buyback program, allowing management to repurchase shares through open market transactions or private negotiations. CEO Lance Alstodt expressed confidence in the company's clinical development pipeline and stated that the current share price does not reflect BioRestorative's intrinsic value. The timing, volume, and value of repurchases will be determined by management based on market conditions and other factors, with flexibility to modify or terminate the program at their discretion.

BioRestorative Therapies (NASDAQ: BRTX) presented promising preliminary data from its Phase 2 clinical trial of BRTX-100, an FDA fast-tracked autologous stem cell therapy for chronic lumbar disc disease (cLDD). The data, presented at ISSCR 2025, showed over 74% of subjects achieved >50% improvement in function and 72% reported >50% pain reduction by week 52. The trial has expanded from 15 to 36 subjects, progressing toward full enrollment of 99 participants. The therapy demonstrated an excellent safety profile with no serious adverse events reported between 26-104 weeks at the target dose. The FDA requires >30% improvement in function (ODI) and pain reduction (VAS) for trial continuation and BLA approval. The results consistently exceeded these thresholds, showing strengthening efficacy markers with each new data analysis.

BioRestorative Therapies (NASDAQ:BRTX) has appointed Sandy Lipkins as a key executive focused on technology commercialization and business development, effective June 9, 2025. Lipkins brings over 30 years of venture capital, finance, and sales experience, with particular expertise in anti-aging and wellness sectors. His responsibilities will include managing strategic alliances and licensing agreements both domestically and internationally. Lipkins has a strong track record in stem cells, regenerative medicine, and tissue banking, along with experience in scaling companies and biologics manufacturing. CEO Lance Alstodt emphasized how Lipkins' expertise aligns with BRTX's mission to advance their clinical pipeline and expand their BioCosmeceuticals platform. The appointment represents a strategic move to accelerate growth and expand market presence in regenerative medicine.

BioRestorative Therapies (NASDAQ: BRTX) announced it will present new preliminary Phase 2 clinical data for BRTX-100, its stem cell therapy for chronic lumbar disc disease, at ISSCR 2025 in Hong Kong. The presentation will reveal blinded safety and efficacy data from 30 patients on June 13, 2025. BRTX-100, the company's lead candidate, is an autologous mesenchymal stem cell therapy targeting areas with limited blood flow. The Phase 2 trial is a randomized, double-blinded, placebo-controlled study across 16 U.S. sites, enrolling 99 patients in a 2:1 ratio of treatment to placebo. CEO Lance Alstodt highlighted strong signals in both safety and functional improvement. The company will release detailed data via press release before market open on June 13th.

BioRestorative Therapies (NASDAQ:BRTX) has reported its Q1 2025 financial results and provided significant clinical updates. The company's BRTX-100 program achieved major milestones, including FDA Fast Track designation for chronic lumbar disc disease (cLDD) treatment and IND clearance for chronic cervical discogenic pain. Preliminary clinical data from the Phase 2 trial showed positive safety profiles and efficacy trends. Financial results showed revenues of $25,000 (down from $35,000 in Q1 2024), with a net loss of $5.3 million ($0.64 per share). The company maintains a strong financial position with $9.1 million in cash and equivalents, with no outstanding debt. In their metabolic program, BioRestorative received a European patent allowance for their ThermoStem® platform and continues discussions regarding potential licensing agreements.